{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":11,"podcast":11,"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01945775\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"EMBRACA","nct_id":"NCT01945775","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=embraca-nct01945775. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"EMBRACA","arms":[{"description":"Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days","label":"talazoparib","type":"EXPERIMENTAL"},{"description":"Capecitabine, Eribulin, Gemcitabine or Vinorelbine","label":"Physician's-Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":["Medivation, Inc."],"completion_date":{"date":"2021-03-05","type":"ACTUAL"},"conditions":["Breast Neoplasms","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation"],"enrollment":{"count":431,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"talazoparib","type":"DRUG"},{"name":"Physician's-Choice","type":"DRUG"}],"last_update":"2022-01-20","lead_sponsor":"Pfizer","official_title":"A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2017-09-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment","timeFrame":"Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)"}],"references":[{"citation":"Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roche HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.","pmid":"35091441","type":"DERIVED"},{"citation":"Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Goncalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.","pmid":"30124753","type":"DERIVED"},{"citation":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.","pmid":"30110579","type":"DERIVED"}],"start_date":{"date":"2013-10-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)","url":"https://clinicaltrials.gov/study/NCT01945775"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/embraca-nct01945775"}